ANI Pharmaceuticals Inc  

(Public, NASDAQ:ANIP)   Watch this stock  
Find more results for NASDAQ:BPAX
-0.34 (-1.18%)
After Hours: 28.47 0.00 (0.00%)
Feb 11, 4:35PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 27.00 - 29.03
52 week 26.80 - 73.54
Open 28.07
Vol / Avg. 0.00/197,425.00
Mkt cap 325.94M
P/E 9.89
Div/yield     -
EPS 2.88
Shares 11.49M
Beta 2.86
Inst. own 91%
Feb 17, 2016
Q4 2015 ANI Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin 22.83% 51.36%
Operating margin 42.31% 35.74%
EBITD margin - 42.67%
Return on average assets 6.61% 18.65%
Return on average equity 11.90% 31.63%
Employees 92 -
CDP Score - -


210 W Main St
BAUDETTE, MN 56623-2467
United States - Map
+1-218-6343500 (Phone)
+1-218-6343540 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


ANI Pharmaceuticals, Inc. (ANI) is an integrated specialty pharmaceutical company engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company's focused areas of product development include narcotics, oncolytics (anti-cancers), hormones and steroids, and complex formulations involving release and combination products. The Company has two pharmaceutical manufacturing facilities located in Baudette, Minnesota that are capable of producing oral solid dose products, as well as liquids and topicals, narcotics, and potent products. The Company's branded products consist of Cortenema, Lithobid, Reglan and Vancocin. Its generic products include Esterified Estrogen with Methyltestosterone, Fluvoxamine Maleate, Hydrocortisone Enema, Methazolamide, Metoclopramide and Opium Tincture. The Company's markets include hormone and steroidal drugs, oncolytics, and narcotics and complex formulations, including extended release and combination products.

Officers and directors

Robert E. Brown Jr. Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Arthur S. Przybyl President, Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Charlotte C. Arnold Chief Financial Officer, Vice President
Age: 50
Bio & Compensation  - Reuters
James G. Marken Vice President - Operations
Age: 52
Bio & Compensation  - Reuters
David J. Sullivan Ph.D. Vice President - Quality Operations
Bio & Compensation  - Reuters
Robert W. Schrepfer Vice President - New Business Development and Contract Manufacturing
Age: 43
Bio & Compensation  - Reuters
Peter A. Lankau Director
Age: 60
Bio & Compensation  - Reuters
Thomas A. Penn Director
Age: 69
Bio & Compensation  - Reuters
Fred H. Holubow Independent Director
Age: 76
Bio & Compensation  - Reuters
Tracy L. Marshbanks Ph.D. Independent Director
Age: 51
Bio & Compensation  - Reuters